GlobeNewswire: Durata Therapeutics, Inc. Contains the last 10 of 59 releaseshttp://www.globenewswire.com/External?Length=42024-03-19T01:21:42ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2014/10/10/672371/10102196/en/Durata-Therapeutics-Presents-New-Data-for-DALVANCE-TM-at-IDWeek-2014-TM.html?f=22&fvtc=4&fvtv=18183Durata Therapeutics Presents New Data for DALVANCE(TM) at IDWeek 2014(TM)2014-10-10T17:34:36Z<![CDATA[Newly Released Clinical and Pre-Clinical Analyses, Including Pharmacokinetics of Dalbavancin in Bone and Associated Tissues in Patients Undergoing Orthopedic Surgical Procedures CHICAGO, Oct. 10, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) today announced a summary of presentation data from its recently launched product, DALVANCE™ (dalbavancin) for injection. The data were presented in five posters at IDWeek 2014, which took place from October 8-11, 2014 in Philadelphia, PA. Among the findings, a study of pharmacokinetic activity in bone and associated tissues demonstrated that dalbavancin accumulates in bone and supports further study in patients with osteomyelitis and prosthetic joint infections. A separate analysis showed patients with ABSSSI who were treated with dalbavancin had similar clinical success rates to those treated with IV vancomycin alone, as well as a tendency to have fewer adverse events and less nephrotoxicity compared to patients who received IV vancomycin for ≥10 days. An examination of ASO and DNase-B titers in patients with streptococcal skin infections in the dalbavancin DISCOVER program was also presented.]]>https://www.globenewswire.com/news-release/2014/10/03/670587/10101141/en/FDA-Grants-Durata-Therapeutics-a-Special-Protocol-Agreement-SPA-for-Its-Phase-3-Study-of-DALVANCE-TM-in-Hospitalized-Community-Acquired-Pneumonia.html?f=22&fvtc=4&fvtv=18183FDA Grants Durata Therapeutics a Special Protocol Agreement (SPA) for Its Phase 3 Study of DALVANCE(TM) in Hospitalized Community-Acquired Pneumonia2014-10-03T12:00:00Z<![CDATA[CHICAGO, Oct. 3, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) today announced that the Company has received a Special Protocol Agreement (SPA) from the Food and Drug Administration (FDA) on the design of its Phase 3 study of DALVANCE (dalbavancin) for injection using a 1500 mg single dose for the treatment of patients with community-acquired pneumonia requiring intravenous therapy.]]>https://www.globenewswire.com/news-release/2014/10/02/670337/10100890/en/Durata-Therapeutics-to-Present-Five-Posters-at-IDWeek-2014.html?f=22&fvtc=4&fvtv=18183Durata Therapeutics to Present Five Posters at IDWeek 20142014-10-02T13:00:00Z<![CDATA[CHICAGO, Oct. 2, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) today announced that it will present five posters highlighting data from its recently launched product, DALVANCE™ (dalbavancin) for injection, at IDWeek 2014, which takes place from October 8-11, 2014 in Philadelphia, PA.]]>https://www.globenewswire.com/news-release/2014/09/09/664718/10097761/en/Durata-Therapeutics-Presented-Data-at-the-54th-Interscience-Conference-on-Antimicrobial-Agents-and-Chemotherapy-ICAAC.html?f=22&fvtc=4&fvtv=18183Durata Therapeutics Presented Data at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)2014-09-09T13:00:00Z<![CDATA[CHICAGO, Sept. 9, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced that data from its recently launched product, DALVANCE™ (dalbavancin) for injection, was presented during the 54]]>https://www.globenewswire.com/news-release/2014/09/03/663417/10096926/en/Durata-Therapeutics-to-Present-Safety-and-Efficacy-Data-at-the-54th-Interscience-Conference-on-Antimicrobial-Agents-and-Chemotherapy-ICAAC.html?f=22&fvtc=4&fvtv=18183Durata Therapeutics to Present Safety and Efficacy Data at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)2014-09-03T13:00:00Z<![CDATA[CHICAGO, Sept. 3, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) today announced that that it will present seven posters highlighting safety and efficacy data from its recently launched product, DALVANCE™ (dalbavancin) for injection, at the 54]]>https://www.globenewswire.com/news-release/2014/08/26/661448/10096095/en/Durata-Therapeutics-Names-Wendy-Yarno-and-J-Martin-Carroll-to-Its-Board-of-Directors.html?f=22&fvtc=4&fvtv=18183Durata Therapeutics Names Wendy Yarno and J. Martin Carroll to Its Board of Directors2014-08-26T21:00:00Z<![CDATA[CHICAGO, Aug. 26, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) today announced that Wendy Yarno and Marty Carroll were added to its Board of Directors at a quarterly meeting of the Board held today. The Company also announced the departure of Mr. Ronald Hunt from its Board, also effective as of this meeting. Ms. Yarno and Mr. Carroll fill an existing vacancy and the position vacated by Mr. Hunt, respectively.]]>https://www.globenewswire.com/news-release/2014/08/07/656859/10093483/en/Durata-Therapeutics-Reports-Second-Quarter-2014-Financial-Results.html?f=22&fvtc=4&fvtv=18183Durata Therapeutics Reports Second Quarter 2014 Financial Results2014-08-07T11:00:00Z<![CDATA[CHICAGO, Aug. 7, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced financial results for the quarter ended June 30, 2014.]]>https://www.globenewswire.com/news-release/2014/08/06/656493/10093148/en/Durata-Therapeutics-to-Present-at-Upcoming-Investor-Conference.html?f=22&fvtc=4&fvtv=18183Durata Therapeutics to Present at Upcoming Investor Conference2014-08-06T12:30:00Z<![CDATA[CHICAGO, Aug. 6, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) announced today that Paul R. Edick, Chief Executive Officer, will present at the Wedbush 2014 Life Sciences Management Access Conference on August 13, 2014 at 9:45am EDT in New York, New York.]]>https://www.globenewswire.com/news-release/2014/07/31/655009/10092180/en/Durata-Therapeutics-to-Report-Second-Quarter-2014-Financial-Results-on-August-7-2014.html?f=22&fvtc=4&fvtv=18183Durata Therapeutics to Report Second Quarter 2014 Financial Results on August 7, 20142014-07-31T12:30:00Z<![CDATA[CHICAGO, July 31, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) has scheduled its quarterly conference call for Thursday, August 7 at 8:30 a.m. Eastern Time to discuss second quarter 2014 financial results.]]>https://www.globenewswire.com/news-release/2014/07/30/654503/10091774/en/Durata-Therapeutics-Enters-Into-an-Exclusive-License-and-Supply-Agreement-With-Angelini-to-Commercialize-Dalbavancin-in-Certain-European-Territories-Russia-and-Turkey.html?f=22&fvtc=4&fvtv=18183Durata Therapeutics Enters Into an Exclusive License and Supply Agreement With Angelini to Commercialize Dalbavancin in Certain European Territories, Russia and Turkey2014-07-30T12:30:00Z<![CDATA[Approximately $80M in Upfront and Milestone Payments CHICAGO, July 30, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) announced today that its Dutch subsidiary, Durata Therapeutics International B.V., has entered into a license and supply agreement with Angelini, an international group leader in the pharmaceutical and mass-market sectors, to commercialize dalbavancin in 36 countries, which include Italy, Spain, Poland, Portugal, many Eastern European countries, Russia, Turkey, and Commonwealth of Independent States.]]>